Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori.

Literature DB >> 2817868

In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori.

J A García-Rodríguez¹, J E García Sánchez, M I García García, E García Sánchez, J L Muñoz Bellido.

Abstract

The in vitro activities of amoxicillin, cefuroxime, ceftetrame, cefetamet, cefixime, tigemonam, erythromycin, roxithromycin, and dirithromycin against 30 clinical isolates of Campylobacter pylori were determined by an agar dilution technique. Roxithromycin and amoxicillin (MICs for 90% of isolates tested, 0.01 and 0.06 micrograms/ml, respectively) were the most active antibiotics tested, but all strains were susceptible to all antimicrobial agents tested.

Entities: Chemical Species

Mesh：

Substances：

Year: 1989 PMID： 2817868 PMCID： PMC172726 DOI： 10.1128/AAC.33.9.1650

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

17 in total

1. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.

Authors: C A McNulty; J C Gearty; B Crump; M Davis; I A Donovan; V Melikian; D M Lister; R Wise
Journal: Br Med J (Clin Res Ed) Date: 1986-09-13

2. Campylobacter pyloridis--a new factor in peptic ulcer disease?

Authors: B J Rathbone; J I Wyatt; R V Heatley
Journal: Gut Date: 1986-06 Impact factor: 23.059

Review 3. Campylobacter pyloridis, gastritis, and peptic ulceration.

Authors: C S Goodwin; J A Armstrong; B J Marshall
Journal: J Clin Pathol Date: 1986-04 Impact factor: 3.411

4. Relation of Campylobacter pyloridis to gastritis and peptic ulcer.

Authors: G E Buck; W K Gourley; W K Lee; K Subramanyam; J M Latimer; A R DiNuzzo
Journal: J Infect Dis Date: 1986-04 Impact factor: 5.226

5. Unidentified curved bacilli on gastric epithelium in active chronic gastritis.

Authors: J R Warren; B Marshall
Journal: Lancet Date: 1983-06-04 Impact factor: 79.321

6. Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin.

Authors: S Czinn; H Carr; S Aronoff
Journal: Antimicrob Agents Chemother Date: 1986-08 Impact factor: 5.191

7. In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).

Authors: H C Neu; N X Chin; P Labthavikul
Journal: Antimicrob Agents Chemother Date: 1986-09 Impact factor: 5.191

8. Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.

Authors: H C Neu; N X Chin; P Labthavikul
Journal: Antimicrob Agents Chemother Date: 1984-08 Impact factor: 5.191

9. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.

Authors: C S Goodwin; P Blake; E Blincow
Journal: J Antimicrob Chemother Date: 1986-03 Impact factor: 5.790

10. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa.

Authors: C A McNulty; J C Dent; G A Ford; S P Wilkinson
Journal: J Antimicrob Chemother Date: 1988-11 Impact factor: 5.790

14 in total

1. In vitro susceptibility of Helicobacter pylori to the new oral cephalosporins cefpodoxime, ceftibuten and cefixime.

Authors: T U Westblom; S Gudipati; B R Midkiff
Journal: Eur J Clin Microbiol Infect Dis Date: 1990-09 Impact factor: 3.267

2. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

Authors: T Iwahi; H Satoh; M Nakao; T Iwasaki; T Yamazaki; K Kubo; T Tamura; A Imada
Journal: Antimicrob Agents Chemother Date: 1991-03 Impact factor: 5.191

3. Activity of cefixime against Helicobacter pylori and affinities for the penicillin-binding proteins.

Authors: F Ikeda; Y Yokota; Y Mine; M Tatsuta
Journal: Antimicrob Agents Chemother Date: 1990-12 Impact factor: 5.191

4. Competition of various beta-lactam antibiotics for the major penicillin-binding proteins of Helicobacter pylori: antibacterial activity and effects on bacterial morphology.

Authors: C R DeLoney; N L Schiller
Journal: Antimicrob Agents Chemother Date: 1999-11 Impact factor: 5.191

5. In vitro activities of irloxacin and E-3846, two new quinolones.

Authors: J A García-Rodríguez; J E García Sánchez; J L Muñoz Bellido; I Trujillano
Journal: Antimicrob Agents Chemother Date: 1990-06 Impact factor: 5.191

6. Multicenter Spanish study of ciprofloxacin susceptibility in gram-negative bacteria. The Spanish Study Group on Quinolone Resistance.

Authors: J A García-Rodríguez; M J Fresnadillo; M I García; E García-Sánchez; J E García-Sánchez; I Trujillano
Journal: Eur J Clin Microbiol Infect Dis Date: 1995-05 Impact factor: 3.267

7. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.

Authors: M Nakao; M Tada; K Tsuchimori; M Uekata
Journal: Eur J Clin Microbiol Infect Dis Date: 1995-05 Impact factor: 3.267

8. Use of cryomicrotomy to study gastric diffusion of amoxicillin in guinea pigs.

Authors: A Lozniewski; M Weber; J D De Korwin; M C Conroy; P Franck; J Floquet; A Le Faou; J C Burdin
Journal: Antimicrob Agents Chemother Date: 1995-03 Impact factor: 5.191

Review 9. Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors: H M Bryson; R N Brogden
Journal: Drugs Date: 1993-04 Impact factor: 9.546

10. Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin.

Authors: F T Counter; P W Ensminger; D A Preston; C Y Wu; J M Greene; A M Felty-Duckworth; J W Paschal; H A Kirst
Journal: Antimicrob Agents Chemother Date: 1991-06 Impact factor: 5.191